We read with great interest the case report “Endovascular treatment of intrarenal aneurysm bleeding and angiomyolipomas in a patient with tuberous sclerosis and polycystic kidney disease” by Leite et al.1 1. Leite T, Pazinato LV, Vidal MJA, Freitas D, Leal Fo JMM. Endovascular treatment of intrarenal aneurysms bleeding and angiomyolipomas in a patient with tuberous sclerosis and polycystic kidney disease. J Bras Nefrol. 2023;45(1):111–5. doi: http://dx.doi.org/10.1590/2175-8239-jbn-2021-0023. PubMed PMID: 34328493. https://doi.org/10.1590/2175-8239-jbn-20... , in which embolization was successfully employed. In cases of bleeding, this preemptive interventional and curative treatment is preferable to partial or total nephrectomy, since it preserves the renal parenchyma and kidney function2 2. Williams JM, Racadio JM, Johnson ND, Donnelly LF, Bissler JJ. Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex. Am J Kidney Dis. 2006;47(1):95–102. doi: http://dx.doi.org/10.1053/j.ajkd.2005.09.028. PubMed PMID: 16377390. https://doi.org/10.1053/j.ajkd.2005.09.0... . Currently, however, the preemptive treatment of choice for tuberous sclerosis-related angiomyolipomas is mTOR inhibitors, not embolization3 3. Bissler JJ, Christopher Kingswood J. Renal manifestation of tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178(3):338–47. doi: http://dx.doi.org/10.1002/ajmg.c.31654. PubMed PMID: 30307110. https://doi.org/10.1002/ajmg.c.31654... ,4 4. Li M, Zhou Y, Chen C, Yang T, Zhou S, Chen S, et al. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet J Rare Dis. 2019;14(1):39. doi: http://dx.doi.org/10.1186/s13023-019-1012-x. PubMed PMID: 30760308. https://doi.org/10.1186/s13023-019-1012-... .